Michael Bernard Martin
Affiliations: | 2001 | University of Illinois, Urbana-Champaign, Urbana-Champaign, IL |
Google:
"Michael Martin"Mean distance: 9.46 | S | N | B | C | P |
Parents
Sign in to add mentor| Eric Oldfield | grad student | 2001 | UIUC | |
| (New chemotherapeutic approaches for the treatment of parasitic protozoan diseases.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wernig G, Kharas MG, Okabe R, et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 13: 311-20 |
| Palanki MS, Akiyama H, Campochiaro P, et al. (2008) Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. Journal of Medicinal Chemistry. 51: 1546-59 |
| Smith BM, Smith JM, Tsai JH, et al. (2008) Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. Journal of Medicinal Chemistry. 51: 305-13 |
| Kousba AA, Soll RM, Yee S, et al. (2007) Cyclic conversion of the novel Src kinase inhibitor [7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) and Its N-oxide metabolite by flavin-containing monoxygenases and cytochrome P450 reductase. Drug Metabolism and Disposition. 35: 2242-2251 |
| Palanki MS, Dneprovskaia E, Doukas J, et al. (2007) Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction. Journal of Medicinal Chemistry. 50: 4279-94 |
| Wernig G, Kharas MG, Okabe R, et al. (2007) Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera. Blood. 110: 556-556 |
| Rodriguez N, Bailey BN, Martin MB, et al. (2002) Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. The Journal of Infectious Diseases. 186: 138-40 |
| Martin MB, Sanders JM, Kendrick H, et al. (2002) Activity of bisphosphonates against Trypanosoma brucei rhodesiense. Journal of Medicinal Chemistry. 45: 2904-14 |
| Szabo CM, Martin MB, Oldfield E. (2002) An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. Journal of Medicinal Chemistry. 45: 2894-903 |
| Szabo CM, Matsumura Y, Fukura S, et al. (2002) Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. Journal of Medicinal Chemistry. 45: 2185-96 |